secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001193805-25-000582
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic's vidofludimus calcium reduces disability worsening risk by 30% in PPMS from phase 2 CALLIPER trial
--------------------------------------------------------------------------------

- Vidofludimus calcium reduced 24-week confirmed disability worsening risk by 20% overall (n=467) vs placebo.
- In PPMS subgroup (n=152), risk reduced by 30%; in non-active SPMS (n=268) by 15%.
- Reduced annualized thalamic brain volume loss by 20% vs placebo; T2 lesion burden improved.
- Safety profile consistent with prior trials: TEAEs 69.4% (drug) vs 68.5% (placebo); SAEs 8.1% vs 6.5%.
- Company plans to discuss phase 3 registration path with healthcare authorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525000582/0001193805-25-000582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525000582/e664445_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-000582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer